Literature DB >> 2422204

Human antibody response to herpes simplex virus-specific polypeptides after primary and recurrent infection.

J Kahlon, F D Lakeman, M Ackermann, R J Whitley.   

Abstract

Human antibody responses to specific polypeptides of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2, respectively) were assessed in serial serum specimens from 18 infected patients by immunoblot technology. Nine patients had HSV-1 infections (six genital and three oral) and nine had HSV-2 genital infections. Antibodies to homologous and heterologous HSV antigens were studied and correlated with total microneutralization and enzyme-linked immunosorbent assay antibodies as well as correlated directly to purified glycoproteins. The data indicated a sequential appearance of antibodies to specific polypeptides, according to virus type and site of infection. After HSV-1 infection, the initial response was to glycoprotein B, but the same was not true for HSV-2 infection, where the initial response appeared to be to the type-specific glycoprotein G. A difference in sequential appearance of antibodies for the two viruses indicated greater reactivity to lower-molecular-weight polypeptides after genital infection, irrespective of type, in contrast to nongenital HSV-1 infections. The antibody responses for selected sera to purified glycoproteins B and D were verified by enzyme-linked immunosorbent assay antibody determinations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422204      PMCID: PMC362825          DOI: 10.1128/jcm.23.4.725-730.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Studies of the natural history of herpes simplex infections.

Authors:  G J BUDDINGH; D I SCHRUM; J C LANIER; D J GUIDRY
Journal:  Pediatrics       Date:  1953-06       Impact factor: 7.124

2.  Complement requirement of neutralizing antibodies appearing after primary and booster immunizations with herpes simplex virus.

Authors:  K Yoshino; T Morishima; Y Aoki
Journal:  Jpn J Microbiol       Date:  1971-01

3.  A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans.

Authors:  R G Douglas; R B Couch
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

4.  Measurement of antibodies to herpesvirus types 1 and 2 in human sera.

Authors:  W E Rawls; K Iwamoto; E Adam; J L Melnick
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

5.  Proteins specified by herpes simplex virus. VI. Viral proteins in the plasma membrane.

Authors:  J W Heine; P G Spear; B Roizman
Journal:  J Virol       Date:  1972-03       Impact factor: 5.103

6.  A serologic study of herpesvirus hominis strains by microneutralization tests.

Authors:  F P Pauls; W R Dowdle
Journal:  J Immunol       Date:  1967-05       Impact factor: 5.422

7.  Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.

Authors:  P W Berman; T Gregory; D Crase; L A Lasky
Journal:  Science       Date:  1985-03-22       Impact factor: 47.728

8.  Polypeptide specificity of the early antibody response following primary and recurrent genital herpes simplex virus type 2 infections.

Authors:  R Eberle; S W Mou; J A Zaia
Journal:  J Gen Virol       Date:  1984-10       Impact factor: 3.891

9.  The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections.

Authors:  D I Bernstein; M A Lovett; Y J Bryson
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

10.  Identification and preliminary mapping with monoclonal antibodies of a herpes simplex virus 2 glycoprotein lacking a known type 1 counterpart.

Authors:  B Roizman; B Norrild; C Chan; L Pereira
Journal:  Virology       Date:  1984-02       Impact factor: 3.616

View more
  9 in total

1.  Highly sensitive enhanced chemiluminescence immunodetection method for herpes simplex virus type 2 Western immunoblot.

Authors:  J Dalessio; R Ashley
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2.

Authors:  D S Schmid; D R Brown; R Nisenbaum; R L Burke; D Alexander; R Ashley; P E Pellett; W C Reeves
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

3.  Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies.

Authors:  D E Goade; R Bell; T Yamada; G J Mertz; S Jenison
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Humoral and cell-mediated immune responses to the glycoproteins of infectious laryngotracheitis herpesvirus.

Authors:  J J York; K J Fahey
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.

Authors:  W D Hunter; R L Martuza; F Feigenbaum; T Todo; T Mineta; T Yazaki; M Toda; J T Newsome; R C Platenberg; H J Manz; S D Rabkin
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Antibody activity to herpes simplex virus in mouse Ig classes and IgG subclasses.

Authors:  R R McKendall; W Woo
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

7.  An automated ELISA using recombinant antigens for serologic diagnosis of B virus infections in macaques.

Authors:  David Katz; Wei Shi; Irina Patrusheva; Ludmila Perelygina; Manjunath S Gowda; Peter W Krug; Chadi N Filfili; John A Ward; Julia K Hilliard
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

8.  Reassessing the detection of B-virus-specific serum antibodies.

Authors:  David Katz; Wei Shi; Martin J Wildes; Peter W Krug; Julia K Hilliard
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

9.  Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.

Authors:  Tamara P Blevins; Michelle C Mitchell; Maria Korom; Hong Wang; Yinyi Yu; Lynda A Morrison; Robert B Belshe
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.